Showing results (521-530 of 1,188) with videos related to
Sort By:
Pageof 119
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 13, 2014
Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromesZhuang Zuo, Sourindra Maiti, Shimin Hu, et al.Applied Optics|August 12, 2025
Compact inverted digital holographic microscope based on common-path configurationIsma Javed, Muhammad Bilal Hassan, Ramna Khalid, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.Cancer|February 28, 2007
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemiaAhmed Aribi, Hagop M Kantarjian, Elihu H Estey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromesGuillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, et al.Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.Applied Immunohistochemistry & Molecular Morphology : AIMM|July 7, 2017
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid LeukemiaTalha Badar, Rajyalakshmi Luthra, Hagop Kantarjian, et al.Cancer|July 25, 2003
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.Journal of Hematology & Oncology|May 2, 2012
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)Azra Raza, Naomi Galili, Deborah Mulford, et al.Clinical Lymphoma, Myeloma & Leukemia|February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.Pageof 119